# Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

> **NCT04806373** · PHASE4 · COMPLETED · sponsor: **Memorial Healthcare System** · enrollment: 27 (actual)

## Conditions studied

- Pleural Effusion

## Interventions

- **DRUG:** Cathflo Activase
- **DRUG:** Talc Slurry Pleurodesis

## Key facts

- **NCT ID:** NCT04806373
- **Lead sponsor:** Memorial Healthcare System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2023-12-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04806373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04806373, "Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04806373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*